174 related articles for article (PubMed ID: 34148711)
1. Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
Wilkinson S; Ye H; Lis RT; Sowalsky AG
Eur Urol; 2021 Sep; 80(3):e83-e84. PubMed ID: 34148711
[No Abstract] [Full Text] [Related]
2. Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
Wyatt AW; Chi KN; Gleave ME
Eur Urol; 2019 Sep; 76(3):e73-e74. PubMed ID: 31167749
[No Abstract] [Full Text] [Related]
3. Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019, 76:871.
Sighinolfi MC; Rocco B
Eur Urol; 2020 May; 77(5):e128-e129. PubMed ID: 32067794
[No Abstract] [Full Text] [Related]
4. Reply to Jérôme Verine's letter to the editor Re: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli. Re: Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Eur Urol 2013;63:400-1.
Montironi R; Lopez-Beltran A; Cheng L; Scarpelli M
Eur Urol; 2013 Jun; 63(6):e74-5. PubMed ID: 23473578
[No Abstract] [Full Text] [Related]
5. Re: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli. Re: Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Eur Urol 2013;63:400-1.
Verine J
Eur Urol; 2013 Jun; 63(6):e72-3. PubMed ID: 23473580
[No Abstract] [Full Text] [Related]
6. Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation.
van Dijk N; Gómez de Liaño Lista A; Szabados B; Powles T; van der Heijden MS
Eur Urol; 2021 Jan; 79(1):e20-e21. PubMed ID: 33153815
[No Abstract] [Full Text] [Related]
7. Re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in radical prostatectomy with no residual carcinoma and with a previous positive biopsy conveys a wrong message to clinicians and patients: why is cancer not present in the radical prostatectomy specimen? Eur Urol 2009;56:272-4.
López JI
Eur Urol; 2010 Mar; 57(3):e21; author reply e22-3. PubMed ID: 19837507
[No Abstract] [Full Text] [Related]
8. Re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol 2010;58:369-73.
Trpkov K; Yilmaz A
Eur Urol; 2011 Mar; 59(3):e5-6; author reply e7-8. PubMed ID: 21134713
[No Abstract] [Full Text] [Related]
9. Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
Tomlins SA; Groskopf J; Chinnaiyan AM
Eur Urol; 2015 Nov; 68(5):e108. PubMed ID: 26242717
[No Abstract] [Full Text] [Related]
10. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
Trock BJ; Karnes RJ
Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
[No Abstract] [Full Text] [Related]
11. Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009.
Chesnut GT; Vertosick EA; Ehdaie B
Eur Urol; 2020 Aug; 78(2):e65-e66. PubMed ID: 32386781
[No Abstract] [Full Text] [Related]
12. Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.028: Despite its Slightly Limited Specificity, Prostate-specific Membrane Antigen Imaging is Still a Game Changer in Prostate Cancer Diagnosis and Therapy Planning.
Ahmadzadehfar H; Essler M
Eur Urol; 2019 Nov; 76(5):e126-e127. PubMed ID: 31151676
[No Abstract] [Full Text] [Related]
13. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033.
Liedberg F; Kollberg P; Allerbo M; Baseckas G; Brändstedt J; Gudjonsson S; Hagberg O; Håkansson U; Jerlström T; Löfgren A; Patschan O; Sörenby A; Bläckberg M
Eur Urol; 2020 Nov; 78(5):e186-e187. PubMed ID: 32950295
[No Abstract] [Full Text] [Related]
14. Reply to Ola Bratt and Anna Öfverholm's Letter to the Editor re: Peter Ström, Tobias Nordström, Henrik Grönberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.028.
Eklund M; Ström P; Nordström T; Grönberg H
Eur Urol; 2018 Jul; 74(1):e10-e11. PubMed ID: 29598984
[No Abstract] [Full Text] [Related]
15. Reply to: Antonio Andrea Grosso, Agostino Tuccio, Matteo Salvi, Daniele Paganelli, Andrea Minervini, and Fabrizio Di Maida's Letter to the Editor re: Paolo Capogrosso, Eugenio Ventimiglia, Giuseppe Fallara, et al. Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.03.018.
Capogrosso P; Ventimiglia E; Fallara G; Schifano N; Costa A; Candela L; Pellegrino F; Colandrea G; Cignoli D; De Angelis M; Belladelli F; Longoni M; Avesani G; Lanzaro F; Scattoni V; Dehò F; Salonia A; Briganti A; Montorsi F
Eur Urol Focus; 2024 Jan; 10(1):207-208. PubMed ID: 37442724
[No Abstract] [Full Text] [Related]
16. Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003.
Uleri A; Baboudjian M; Diamand R; Ploussard G
Eur Urol; 2024 May; ():. PubMed ID: 38796380
[No Abstract] [Full Text] [Related]
17. Reply to Can Lu and Xiao Guan's Letter to the Editor re: Marko Babjuk. Are the Role of Surgery and its Complications Sufficiently Focused in the Era of Perioperative Systemic Treatments? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.01.022.
Babjuk M
Eur Urol; 2020 Aug; 78(2):e73-e74. PubMed ID: 32389446
[No Abstract] [Full Text] [Related]
18. Reply to Glen Denmer Santok and Koon Ho Rha's Letter to the Editor re: Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.07.023.
Stattin P; Bratt O
Eur Urol; 2017 Apr; 71(4):e115-e116. PubMed ID: 27720538
[No Abstract] [Full Text] [Related]
19. Reply to E. David Crawford and Bo-Eric Persson's letter to the editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026.
Gandaglia G; Sun M; Briganti A; Karakiewicz PI
Eur Urol; 2014 Aug; 66(2):e36-7. PubMed ID: 24746970
[No Abstract] [Full Text] [Related]
20. Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
Stephan C; Cammann H; Jung K
Eur Urol; 2015 Nov; 68(5):e106-7. PubMed ID: 26215600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
